Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
CLLSCellectis(CLLS) Newsfilter·2024-04-30 04:46

•   Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting •   Execution of strategic collaboration and investment agreements with AstraZeneca •   Cécile Chartier, Ph.D., appointed as a director of the Cellectis' Board of Directors •   Drawdown of the second tranche of €15 million under the credit facility agreement entered into with the European Investment Bank (EIB) •   Cash position of $156 milli ...